MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Clinical trials for MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shrinks spleens in bone marrow cancer patients
Disease control CompletedThis study tested a new drug called pelabresib in people with certain blood cancers, including myelofibrosis and leukemia. In the first part, the drug was given alone to find the safest dose. In the second part, it was given with or without another drug (ruxolitinib) to see if it…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: Constellation Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Experimental combo targets Hard-to-Treat blood cancers
Disease control CompletedThis early-phase study tested a new drug called TGR-1202 combined with the standard drug ruxolitinib in 60 people with myelofibrosis or polycythemia vera. The goal was to see if the combination is safe and tolerable. Participants either had not responded well to ruxolitinib alone…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Blood cancer enzyme deficiency explored in new study
Knowledge-focused CompletedThis study looked at how often people with certain blood cancers or related conditions have an acquired deficiency of an enzyme called pyruvate kinase, which can cause anemia. Researchers took a single blood sample from 18 participants to measure enzyme activity and check for rel…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC